Blinatumomab is a bispecific T-cell engager that redirects cytotoxic T cells against leukemia cells. The AIEOP-BFM ALL 2017 trial evaluated whether two highly intensive chemotherapy blocks could be replaced by two cycles of blinatumomab in newly diagnosed high-risk pediatric B-ALL.

A total of 709 patients were randomized following induction and consolidation therapy.

Safety Outcomes-

• Clinically relevant infectious adverse reactions: 69.4% chemotherapy patients vs. 22.8% blinatumomab (p < 0.001). 

• Neurologic adverse reactions: 2.9% chemotherapy group vs. 11.7% blinatumomab (p < 0.001). 

• Patients hospitalized for severe mucositis/stomatitis: 10% chemotherapy vs. 0.3% blinatumomab. 

• Cytokine release syndrome ≥ Grade 2 was rare in the blinatumomab (1.1%). 

• Sixteen patients (4.7%) had 17 life-threatening adverse reactions in the chemotherapy group vs. one in the blinatumomab group (as well as fatal, 0.3%). 

• Among transplanted patients, the non-relapse mortality was 16% in the chemotherapy (n = 12/73) compared with 2.5% in the blinatumomab (n = 2/79).

KOL Insights-

“The replacement of 2 highly intensive chemotherapy courses by 2 cycles of blinatumomab given [intravenously] improved the [EFS] significantly in [patients with] high-risk B-ALL. Both systemic- and central nervous system [CNS] related relapses have been reduced by replacing chemotherapy in favor of introducing blinatumomab.”– Expert Opinion

“For the first time, in newly diagnosed ALL, highly toxic chemotherapy elements have successfully been replaced by blinatumomab, demonstrating a safer but also superior anti-leukemia efficacy of immunotherapy in prognostically unfavorable pediatric B-ALL.”– Expert Opinion

Conclusion-

Acute lymphoblastic leukemia (ALL) is the most common childhood cancer, accounting for approximately 25% of all pediatric malignancies. B-cell ALL represents nearly 80–85% of childhood ALL cases. Although cure rates now exceed 85%, outcomes remain poorer for high-risk patients, and treatment-related toxicity continues to be a major cause of morbidity and mortality.

The Phase III AIEOP-BFM ALL 2017 trial represents a landmark advance in pediatric leukemia treatment. By replacing two highly intensive chemotherapy blocks with blinatumomab, investigators achieved significantly superior EFS, lower relapse rates, deeper MRD responses, and substantially improved safety outcomes. Importantly, reductions in infections, severe mucositis, life-threatening adverse events, and transplant-related mortality demonstrate that chemotherapy intensity can be safely reduced without compromising and indeed improving anti-leukemic efficacy. These findings are likely to establish blinatumomab-based chemotherapy reduction as a new standard of care for newly diagnosed high-risk pediatric B-ALL.